SHANGHAI FOSUN PHARMACEUTICAL Aktie

 

CLSA issued a report stating that FOSUN PHARMA (02196.HK)'s results for 1Q26 slightly missed market expectations. Although revenue and profit recorded solid growth, mainly driven by the innovative drug segment, the healthcare services segment continued to face pressure. Nevertheless, management remains confident in achieving the......

SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million,......

FOSUN PHARMA (02196.HK) announced its first-quarter results, with revenue of RMB10.073 billion, up 6.9% YoY. Net profit attributable to shareholders amounted to RMB871 million, representing a 13.9% YoY increase. EPS was RMB0.33. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by A......

Strategic framework established for regional and global licensing, frontier technology incubation, and strategic collaboration in neurodegenerative diseases Joint R&D aligned with China-UAE bilateral partnership and Abu Dhabi's Healthcare Life Sciences Vision 2030 SHANGHAI, April 28, 2026......

Morgan Stanley said in a research report that it raised Fosun Pharma (02196.HK)'s revenue forecasts for 2026 to 2028 by 3%, driven by higher sales of innovative drugs and expected recurring licensing income of approximately RMB800 million per year.Meanwhile, it lowered net profit forecasts by 1%, 1% and raised by 4%, respectivel......

Fosun Pharma (02196.HK) announced that its subsidiary Fosun Kairui has received approval from the National Medical Products Administration to conduct Phase I/II clinical trials of FKC289 injection for relapsed/refractory primary light-chain amyloidosis and relapsed/refractory membranous nephropathy. Fosun Kairui plans to carry o......

FOSUN PHARMA (02196.HK) announced that its subsidiary HENLIUS (02696.HK) has received approval from the National Medical Products Administration to conduct a Phase I clinical trial of HLX05-N (recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection) for the treatment of metastatic colorectal cancer. HENLIUS plan......

Fosun Pharma (02196.HK) announced that the board of directors has received a written resignation letter from Chen Zhanyu. Due to adjustments in work arrangements, Chen Zhanyu has applied to resign as Chief Financial Officer, effective April 2. Following the resignation, Chen Zhanyu will continue to serve as Senior Vice President......

Fosun Pharma (02196.HK) announced that its subsidiary, Shanghai Henlius Biotech and its holding subsidiary Henlius, have received approval from the National Medical Products Administration for HLX319 (pertuzumab-trastuzumab injection (subcutaneous) biosimilar) to conduct a Phase I clinical trial for neoadjuvant therapy in HER2-p......

Fosun Pharma (02696.HK) announced that the National Medical Products Administration (NMPA) has approved the Phase 1 clinical trial application (INDs) for its independently developed biosimilar injection HLX319 (subcutaneous injection) of pertuzumab-trastuzumab. The company plans to conduct related clinical trials in China once c......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Fosun Pharma (02696.HK) announced that the Phase 1 clinical trial application (IND) for its independently developed HLXTEHAase02 (recombinant human hyaluronidase injection) has been approved by the National Medical Products Administration (NMPA). The company plans to conduct the related clinical trials within mainland China (exc......

Fosun Pharma (02696.HK) announced that its independently developed Slulitinib Injection (HANSIZHUANG, HETRONIFLY) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The recommendation is to approve HANSIZHUANG in combination with fluoropyrimidine and platin......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and healthcare group, announced its 2025 annual......

A unit of Fosun Pharma has struck a US$1.55 billion deal to license its home-grown cancer drug to Japan's Eisai, adding to a wave of out-licensing agreements that are channelling billions of dollars into Chinese novel drug development. The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners, shifting from simple one-off licensing fees, where a company is paid for granting rights to its drug, to long-term collaborations. Under......

The board of Shanghai Fosun Pharmaceutical approved the spin-off and Hong Kong listing of its vaccine unit, aiming to bolster the business as biotechnology shares continue to outperform in the city's stock market. The board cleared the proposed spin-off of Fosun Adgenvax (Chengdu) Biopharmaceutical for a Hong Kong initial public offering (IPO) on Thursday, according to a late filing by Fosun Pharma, whose shares are listed in Shanghai and Hong Kong. The filing did not disclose the planned IPO......

Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and......

US-Pharmariesen verlieren Patentschutz im Marktwert von Milliarden Dollar. Chinesische Biotechs liefern Ersatz. Was heißt das für den globalen Pharma-Markt?...